Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Case of Lung Adenocarcinoma Resistant to Crizotinib Harboring a Novel EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Oct 2016

Anai Satoshi, Takeshita Masafumi, Ando Nobuhisa, Ikematsu Yuuki, Mishima Shohei, Ishida Koichi, Inoue Kouji

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Crizotinib
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Gene Rearrangement

Share to Oncogene Proteins, Fusion

Share to Protein Kinase Inhibitors

Share to Pyrazoles

Share to Pyridines

Source

Identifiers

PMID: 27663401
DOI: 10.1016/j.jtho.2016.07.008

Genes

ALK
EML4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Case of Lung Adenocarcinoma Resistant to Crizotinib Harboring a Novel EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK.PMID 27663401Read ↗

Lung adenocarcinoma harboring concomitant EGFR mutation and EML4-ALK fusion that benefits from three kinds of tyrosine kinase inhibitors: a case report and literature review.Semantic proximity Read ↗

Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer.Semantic proximity Read ↗

Novel NLRC4-ALK and EML4-ALK double fusion mutations in a lung adenocarcinoma patient: A case report.Semantic proximity Read ↗

Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene.Semantic proximity Read ↗

Acquired resistance to crizotinib in advanced lung adenocarcinoma with MET exon 14 skipping.Semantic proximity Read ↗

Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung CancerSemantic proximity Read ↗

BRAF V600E mutation as a novel mechanism of acquired resistance to ALK inhibition in ALK-rearranged lung adenocarcinoma: A case report.Semantic proximity Read ↗

A Case Report of Successful Treatment With Crizotinib to Overcome Resistance to Osimertinib in an EGFR Mutated Non-Small-Cell Lung Cancer Patient Harboring an Acquired MET Exon 14 Mutation.Semantic proximity Read ↗

[Mechanisms of resistance to crizotinib in patients with transforming EML4-ALK fusion gene].Semantic proximity Read ↗

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.Semantic proximity Read ↗

Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation.Semantic proximity Read ↗

Lung adenocarcinoma with concurrent KRAS mutation and ALK rearrangement responding to crizotinib: case report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.